NCT07606833尚未招募3 期
A Multicenter, Randomized, Double Blind, Double-simulated, Parallel Control of Positive Drug Phase III Clinical Study Evaluating the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Containing Bismuth in Quadruple Therapy for the Eradication of Helicobacter Pylori
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 556
- 试验地点
- 1
研究概览
简要总结
This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole versus Esomeprazole-containing Bismuth quadruple therapy for eradication of Helicobacter pylori in China.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18-75 years
- •During the screening visit, the participants were determined to be Hp-positive by 13C-UBT and Hp eradication therapy was required by the investigator.
- •Fully understand the content of the experiment, voluntarily participate in the experiment, and sign the informed consent.
排除标准
- •Known allergic history to Anaprazole or Esomeprazole, or amoxicillin or clarithromycin and bismuth(including any related excipients ).
- •Have a history of severe rapid-onset hypersensitivity to β-lactam agents (such as cephalosporins, carbapenems, monocyclic β-lactam).
- •The participant has Zollinger-Ellison syndrome.
- •Participants known to have acute upper gastrointestinal bleeding, active gastric or duodenal ulcer, acute gastric mucosal injury (AGML) or acute duodenal mucosal injury (ADML).
- •Participants in the trial had previously undergone surgeries or procedures that might affect gastric acid secretion or drug absorption.
- •Participants with a history of malignant tumors within 5 years prior to screening (Cutaneous basal cell carcinoma or cervical carcinoma in situ that has been cured is excluded).
- •The subject has severe central nervous system, cardiovascular, respiratory, liver, kidney, gastrointestinal, urinary, endocrine or hematological diseases that the investigator believes may affect the study results and the safety of the participants.
- •Laboratory examination during the screening period showed ALT or AST > 2 times of the upper limit of normal value, TBIL > 1.5 times of the upper limit of normal value; renal function Cr > 1.5 times of the upper limit of normal value (one review was allowed in the study, and those who still did not meet the requirements for inclusion were excluded).
- •Participants with severe arrhythmia, multigenic premature ventricular contractions (PVC), second-degree or higher atrioventricular block, ventricular arrhythmia or prolonged QT interval (QTcF> 450ms in male and 470ms in female).
- •Previously received Helicobacter pylori eradication treatment.
- •Used PPI or P-CAB preparations within 2 weeks before 13C-UBT examination during the screening period; Antibiotics, bismuth-containing preparations, or traditional Chinese medicine with antibacterial effects were used within 4 weeks before 13C-UBT test during the screening period.
- •Those with chronic drug abuse in the 12 months prior to screening.
- •Those with alcohol dependence in the 12 months prior to screening.
- •Participated used experimental drugs/devices in other drug/device clinical studies within 3 months before screening.
- •Female participants who are suspected or already pregnant, breastfeeding; and female participant or a partner of male participant who are planning to become pregnant during the study.
- •Others were deemed unsuitable for the trial .
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPDNCT07314242Ganzhou Hemay Pharmaceutical Co., Ltd120
招募中
3 期
This is a comparative phase III clinical trial in an eye condition called WET AMD. A study of an eye injection Aflibercept for improving vision and assessing safety in patients. Total 382 subjects will be enrolled in the study. The main outcome is to demonstrate the efficacy of RLS-afliberceptCTRI/2025/10/095593Reliance Life Sciences Pvt. Ltd382
已完成
3 期
A Clinical Study to Evaluate the Efficacy and Safety of Diltiazem Gel in Subjects with Chronic Anal Fissure.CTRI/2024/12/078489Morningside Healthcare266
尚未招募
3 期
A Phase III Study of GS101 Injection to Dupixent®NCT07386743Jiangsu Genscend Biopharmaceutical Co., Ltd572
尚未招募
1 期
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved OcrevusMultiple SclerosisNCT07606521Polpharma Biologics International AG222